Ind-Swift Laboratories has bagged its first Contract Research and Manufacturing Services (CRAMS) order from a Leading European Pharmaceutical Company. The said contract will help the company towards its goal to achieve the revenues from CRAMS.
Strategically, the company has decided to focus on CRAMS as it has state of the art research and development (R&D) centre equipped with latest equipments and top class scientific talent, to handle such contracts and generate additional revenues and better profitability.
For FY 2012-13, the company expects CRAMS to generate around Rs 10 crore additional revenues.
Ind-Swift Laboratories is a part of the Ind-swift Group and is based at Chandigarh, India. The company is engaged in manufacturing of Active Pharmaceutical Ingredients (API).
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: